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Pepression in Heart Failure
Meta-Analytic Review of Prevalence,
ntervention Effects, and Associations With Clinical Outcomes
homas Rutledge, PHD,*† Veronica A. Reis, BSC,*‡ Sarah E. Linke, BA,§
arry H. Greenberg, MD, FACC,† Paul J. Mills, PHD†
an Diego and Los Angeles, California
This article describes a meta-analysis of published associations between depression and heart
failure (HF) in regard to 3 questions: 1) What is the prevalence of depression among patients
with HF? 2) What is the magnitude of the relationship between depression and clinical
outcomes in the HF population? 3) What is the evidence for treatment effectiveness in
reducing depression in HF patients? Key word searches of the Medline and PsycInfo
databases, as well as reference searches in published HF and depression articles, identified 36
publications meeting our criteria. Clinically significant depression was present in 21.5% of HF
patients, and varied by the use of questionnaires versus diagnostic interview (33.6% and
19.3%, respectively) and New York Heart Association–defined HF severity (11% in class I vs.
42% in class IV), among other factors. Combined results suggested higher rates of death and
secondary events (risk ratio  2.1, 95% confidence interval 1.7 to 2.6), trends toward
increased health care use, and higher rates of hospitalization and emergency room visits
among depressed patients. Treatment studies generally relied on small samples, but also
suggested depression symptom reductions from a variety of interventions. In sum, clinically
significant depression is present in at least 1 in 5 patients with HF; however, depression rates
can be much higher among patients screened with questionnaires or with more advanced HF.
The relationship between depression and poorer HF outcomes is consistent and strong across
multiple end points. These findings reinforce the importance of psychosocial research in HF
populations and identify a number of areas for future study. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.0551527–37) © 2006 by the American College of Cardiology Foundation
e
t
(
r
i
n
s
e
s
1
i
p
a
o
d
o
m
W
i
M
A
a
i
r
wver the past 2 decades, associations between clinical
epression and cardiovascular disease risk have become an
ncreasingly common, if not always consistent, finding in
he cardiovascular literature (1–4). Meta-analytic reviews of
he depression relationship with heart disease outcomes
rovide strong evidence for prospective connections be-
ween depression and the incidence of coronary artery
isease (CAD) (5,6), between depression and premature
ortality among patients with documented CAD (7,8), and
etween depression and all-cause mortality in populations
ith and without CAD (9). However, despite these asso-
iations, there has yet to be a successful randomized inter-
ention trial for depression affecting objective clinical out-
omes (10), raising important questions about the biological
ole of depression in CAD.
The surge of research interest in depression and CAD has
arried over into related cardiovascular diseases. Heart
ailure (HF), a condition affecting nearly 5 million patients
n the U.S. alone, has become a major focus of depression
esearch in recent years, with a growing number of publi-
ations suggesting poorer clinical outcomes for HF patients
eporting symptoms of depression (11–14). Research inter-
From the *VA San Diego Health Care System, San Diego, California; †University
f California, San Diego, San Diego, California; ‡University of Southern California,
os Angeles, California; and §San Diego State University/University of California,
an Diego Joint Doctoral Program in Clinical Psychology, San Diego, California.
avid S. Sheps, MD, MSPH, acted as the guest editor for this article.d
Manuscript received March 6, 2006; revised manuscript received May 10, 2006,
ccepted June 16, 2006.st in the psychosocial dimensions of HF is reinforced by
he enormous health care costs associated with the condition
15,16), as well as by the high rates of clinical depression
eported among patients with HF in numerous studies (17,18).
Although recent literature reviews of depression and HF
dentify important themes (19,20), quantitative methods are
ecessary to precisely define the magnitude of the relation-
hip between clinical depression and HF. To our knowl-
dge, this article is the first meta-analytic review of depres-
ion and HF. The focus was guided by 3 primary questions:
) What is the prevalence of clinically significant depression
n HF? To what extent is the heterogeneity in reported
revalence estimates explained by differences in depression
ssessment methods, HF severity, age, gender composition,
r other demographic characteristics? 2) What is the evi-
ence for longitudinal associations between depression and
bjective clinical outcomes in HF, including HF incidence,
ortality and cardiovascular events, and hospitalization? 3)
hat are the effects of pharmacologic and nonpharmacologic
nterventional efforts on depression among patients with HF?
ETHODS
rticle selection and literature search. Using the Medline
nd PsycInfo databases, two of the authors (V.R. and S.L.)
ndependently identified relevant articles published in peer-
eviewed journals by September 12, 2005. Primary key
ords included depression and HF, congestive heart failure,
epressive disorder, depressive symptoms, quality of life,
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Depression and Heart Failure October 17, 2006:1527–37sychosocial factors, stress, cardiomyopathy, emotional fac-
ors, psychological distress, and mental health. Subse-
uently, these abstracts were reviewed for inclusion based on
ssessments of the published article. We identified addi-
ional eligible articles using references from the articles
ollected through the database search. Criteria for selection
ncluded the following: 1) reporting a rate of depression
sing either clinical interview or a validated questionnaire;
) describing prospective relationships between depression
nd mortality, secondary cardiovascular events, rehospital-
zation, or health care costs; and 3) documenting changes in
epression, measured before and after treatment, attributed
o an intervention. In cases in which articles contained
nsufficient statistics, we attempted to contact the study’s
rimary investigators to provide additional information. All
tudies required the use of a sample composed exclusively of
atients diagnosed with HF, or the reporting of statistics
pecifically for a patient subgroup with HF. Using the
forementioned methods, we identified a total of 36 inde-
endent articles. These include 27 articles reporting depres-
ion prevalence information, 14 describing prospective as-
ociations between depression and HF outcomes, and 6
eporting depression changes from treatment (some con-
ained multiple association types, accounting for the non-
dditive article total).
epression measures. Depression diagnostic methods fell
nto 3 primary categories: 1) clinical interviews, including
he Structured Clinical Interview for the Diagnostic and
tatistical Manual of Mental Disorders, Fourth Edition
21), Structured Clinical Interview for the Diagnostic and
tatistical Manual of Mental Disorders, Fourth Edition–
onpatient Edition (22), Diagnostic Interview Schedule for
epression (23), Modified Diagnostic Interview Schedule
or Depression (24), Composite International Diagnostic
nterview Short Form (25), and Primary Care Evaluation of
ental Disorders (26); 2) depression symptom inventories,
ncluding the Beck Depression Inventory (BDI) (27), Zung
elf-Rating Depression Scale (28), Geriatric Depression
cale (29), Center for Epidemiological Studies–Depression
cale (30), Hospital Anxiety and Depression Scale (31),
nventory to Diagnose Depression (32), Hamilton Rating
cale for Depression (33), the depression scale from the
opkins Symptom Checklist (34), Medical Outcomes
tudy–Depression (35), and the Multiple Affect Adjective
hecklist (36); and 3) a diagnosis of depression based on the
atient’s medical record (e.g., International Classification of
iseases, 9th Edition code) or use of antidepressant
Abbreviations and Acronyms
BDI  Beck Depression Inventory
CAD  coronary artery disease
HF  heart failure
IL  interleukin
NYHA  New York Heart Associationedication. CIn several cases, investigators used more than 1 of the
reviously mentioned criteria. For example, a number of
rticles used questionnaires as screening tools, and higher-
coring patients were subsequently interviewed for evidence
f a major depressive disorder.
atabase construction and coding. Because of the relative
ndependence of our review questions, we developed sepa-
ate databases for the prevalence, clinical outcome, and
reatment effects themes. Some studies contributed to more
han 1 database (e.g., by reporting baseline depression
revalence in addition to a prospective or intervention
omponent).
From studies describing depression prevalence, we coded
epression rates by HF severity, gender, minority status,
tudy location, depression assessment method, mean age,
nd inpatient/outpatient status, as available. Several studies
ncluded sample information regarding HF subtypes (e.g.,
schemic vs. nonischemic HF), however, there were not
ufficient data from which to make depression comparisons
cross different forms of HF. The coding scheme defined
epression assessment methods according to the use of
uestionnaires, clinical interviews, or patient medical
ecords/patient use of antidepressants. We also categorized
revalence rates from individual studies as either “conserva-
ive” or “liberal” depending on the rigor of their criteria for
lassifying participants as depressed. To qualify as conser-
ative, a prevalence rate had to meet one or more of the
ollowing criteria: included an interview component, exam-
ned patients’ medical records for evidence of a formal
iagnosis of depression, or used a questionnaire with a cutoff
hat explicitly screened for moderate to severe depression
representative of a DSM diagnosis) as opposed to mild
epression or depressive symptoms. An example of a con-
ervative versus a liberal cutoff is a score of 17 versus 10 on
he BDI. All other rates were classified as liberal: most of
hem were determined from using a lower cutoff on a
alidated questionnaire, whereas 1 rate (15) was based on
vidence of an antidepressant prescription without an ac-
ompanying diagnosis of depression in the patients’ medical
ecords, and therefore, could have included patients taking
ntidepressants for other reasons (e.g., sleep or smoking
essation). Studies that used 2 cutoffs (1 conservative and 1
iberal) and reported separate rates for each were represented
n both categories.
The categorization of treatment studies included sorting
y intervention type and study duration. Because of the
mall number of available treatment studies, we did not
xclude studies based on qualitative factors. All of the
dentified treatment studies assessed depressive symptoms
ia questionnaires before and after treatment; treatment
ffects were determined, in part, by comparing changes in
cores between these 2 time periods.
From the longitudinal outcome studies, we categorized
tudies by duration, study method, level of covariate adjust-
ent, and type of clinical outcome, among other variables.
linical outcomes included HF incidence, health care costs
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October 17, 2006:1527–37 Depression and Heart Failuressociated with HF, hospitalization, and combined clinical
utcomes in the form of death and secondary events. As
ith the prevalence articles, the sorting of depression
ssessment methods used categories reflecting the use of
uestionnaires, diagnostic interviews, or patient medical
ecords. The coding of all articles included demographic
nformation (i.e., gender, age, and minority composition),
ample size, inpatient and outpatient sample type, and study
ocation (e.g., U.S., Europe).
uantitative methods. The software SPSS, version 11.5
SPSS Inc., Chicago, Illinois), and Comprehensive
etaAnalysis, Version 2 (BioStat Software, Engelwood,
ew Jersey), served as the statistical platforms for com-
leting all statistical tests and associated graphic results.
or the summation of the prevalence findings, we com-
uted prevalence point estimates and 95% confidence
ntervals using the formulas Logit Event Rate  Log
Event Rate / (1  Event Rate)], Logit Event Rate SE 
1⁄Event Rate  Num Tot  1 / [(1 Event Rate)
um Tot], and 95% confidence intervals as Lower Limit 
ogit Event Rate  (1.96  Logit Event Rate SE) and
pper Limit  Logit Event Rate  (1.96  Logit Event
ate SE). To standardize results for meta-analytic summary
n the clinical outcomes articles, we converted reported odds
atios into risk ratio values using the formula: risk ratio 
dds ratio/([1  P0]  [1  P0]), where P0 represents the
ncidence of the outcome in the nonexposed (nondepressed)
roup (37).
We centered the display of prevalence estimates around a
oint of 0.50 to provide a reference standard for purposes of
llustration. In addition to the overall random effects model,
ensitivity analyses broke down prevalence results across a
umber of methodologic factors to assess evidence of
oderation. These factors included gender, minority status,
epression assessment method, HF severity, and use of
npatient versus outpatient HF patient samples.
The small number of overall treatment studies and the
ixed nature of the interventions prohibited the use of
eta-analytic tests for this section. Descriptive summa-
ies of the treatment articles divided studies on the basis
f using pharmacologic versus nonpharmacologic inter-
entions. We calculated effects sizes for the treatment
tudies in the form of Cohen d values according to the
ormula d  M1  M2/spooled. To address the issue of
ublication bias, a fail-safe N was calculated using the
omprehensive Meta-Analysis software program (Bio-
tat).
Heterogeneity assessments preceded all meta-analytic
ests concerning depression prevalence and clinical out-
omes. In each case regarding prevalence rate analysis, there
as significant heterogeneity, hence we calculated results
sing a random effects model and reported corresponding p
alues and I2 values. Clinical outcome article categories
ncluded HF incidence, health care use and hospitalization,
nd mortality and clinical events. The number of mortality- npecific findings was insufficient to assess this outcome
ndependently. Log-transformed risk ratios and 95% confi-
ence intervals were calculated for each study using the
eported effect size and estimates of the standard error of
ach effect drawn from data reported in the article. When
rticles reported multiple models, we selected the model
ith the highest level of covariate adjustment. In cases in
hich parallel models from different time points were
vailable, we used the model with the longest time estimate,
xcept in cases in which we extracted both short-term and
onger-term model results for comparisons as described.
ESULTS
revalence. Figure 1 shows the prevalence rates of clini-
ally significant depression among HF patients reported for
ach of the 27 studies and an aggregated estimate of
pproximately 21.5%, determined using meta-analytic tests
previously described). The failsafe N statistic indicated that
n additional 8,680 missing studies were required to bring
he p value from 0.00 to 0.05. The prevalence rates reported
cross these studies varied widely, ranging from 9% (38) to
0% (39).
Sixteen of the 27 studies included sufficient data regard-
ng gender to analyze prevalence rates of depression in male
nd female HF patients (12,15,17,18,38–60). The aggre-
ated prevalence rate for women was higher than that for
en, with point estimates of 32.7% (p 0.000; I2 89.2%)
nd 26.1% (p  0.000; I2  94.4%), respectively. Reported
anges again varied widely, with a range of 11% (40) to 67%
41) for women and 7% (15) to 63% (42) for men.
Ten of the 27 studies provided prevalence rates of
epression among HF patients broken down by race or
thnicity. The range of minority prevalence rates was 7% to
4% with an aggregated estimate of 18.7% (p 0.000; I2
5.2%). In comparison, Caucasian HF patients within the
ame 10 studies had a depression prevalence range of 9% to
4% with an aggregated estimate of 25.3% (p 0.000; I2
1.2%). Thus, there was some evidence of depression
ifferences between minority and nonminority ethnic
roups. Minority groups included within these 9 studies
ere African Americans, Afro-Caribbeans, Asians, Native
mericans, and Pacific Islanders. An attempt to break
hese data down further for analysis by ethnicity was not
easible because of the heterogeneity of groups and small
ample sizes.
An analysis of the reported prevalence rates of depression
n HF patients based on 5 studies that presented sufficient
ata for analysis by New York Heart Association (NYHA)
unctional class showed an aggregated estimate of 27.8%
p  0.001; I2  92.1%) and higher prevalence rates
ssociated with higher NYHA functional class (Table 1).
lthough the differences between prevalence rates for pa-
ients within classes I or II and classes III or IV are similar,
he rate of depression in patients with class III HF was
early double that of patients with class II HF. We further
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Depression and Heart Failure October 17, 2006:1527–37bserved a nearly 4-fold increase in depression rates between
atients with class I and class IV HF. The depression and
F class relationship may further be affected by age, as
hown by Freedland et al. (17), with younger patients (60
ears) being more vulnerable to depression.
Figure 1. Prevalence of depression in heart failur
able 1. Depression Prevalence Reported by NYHA Functional
lass in Patients With HF
NYHA Functional Class n* Depression Rate
I 222 0.11
II 774 0.20
III 638 0.38
IV 155 0.42
Estimates compiled from 5 studies reporting depression rates among specific NYHAp
unctional classes of HF patients.
HF  heart failure; NYHA  New York Heart Association.Prevalence rates by the type of assessment measure used
anged from 10% to 54%. The method of assessment was then
ichotomized into “questionnaires” or “interview included.”
ompared with the aggregate depression rate of approximately
2%, prevalence estimates for patients assessed solely with
uestionnaires versus those whose assessment included an
nterview were 33.6% (heterogeneity p  0.001, I2  90.3%)
nd 19.3% (p  0.001, I2  94.1%), respectively. Depression
as assessed with both a self-report questionnaire and an
nterview component in 9 of the 26 studies, solely an interview
n 2 of the 26 studies; the combined prevalence rate reported in
hese studies was approximately 17.7%, nearly 25% less than
he overall aggregate rate. The remaining studies used self-
eport questionnaires alone to assess depression and re-
ients, and 95% confidence intervals (27 studies).orted prevalence rates ranging from 30% to 44%. When
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October 17, 2006:1527–37 Depression and Heart Failurehe studies that used the same depression measure were
ombined and compared with each other, the rates differed.
The overall weighted conservative prevalence depres-
ion rate mean (based on 9 studies with 5,053 partici-
ants) was 20.3% (p  0.000; I2  86.7%), whereas the
verall weighted liberal prevalence depression rate mean
based on 13 studies with 5,376 participants) was 35.5%
p  0.000; I2  95.5%).
The data were also analyzed for differences in depression
revalence rates among inpatient and outpatient HF pa-
ients. Five of the 27 studies included for prevalence data
ere designed to measure participants’ depression levels
ver time and hence captured data while participants were
oth inpatients and outpatients; thus, these studies were
oded as “combined” for this portion of the analysis. Of the
2 studies with participants who were not considered
ombined, 10 fell into the inpatient category and 12 fell into
he outpatient category.
Although overall results suggested no important differ-
nces between inpatient and outpatient samples, we were
oncerned about the risk of measurement bias such that
utpatients may have been more likely to be assessed with
uestionnaires. As shown in Table 2, we addressed this
oncern formally by examining 14 studies that reported
epression rates using either a conservative cutoff, a liberal
utoff (e.g., 17 vs. 10 on the BDI), or both. Even broken
able 2. Depression Rates Among Heart Failure Patients by Inp
Depression Prevalence Rates Among Patient Classifications
Using Conservative Cutoffs*
Patient
Classification
Prevalence
Rate (SD)
Number of Studies,
(Patients)
Inpatient 0.16 (0.09) 8 (2,921)
Outpatient 0.14 (0.02) 8 (1,095)
Combined 0.14 (0.06) 3 (1,037)
Conservative depression definitions included protocols with a structured interview, d
utoff in the case of measures with multiple cutoff points.
able 3. A Description of HF Studies Reporting Relationships B
Study Depression Measure Duration
bramson et al. (61) CES-D 4.5 yrs 
illiams et al. (44) CES-D 14 yrs 
imelhoch et al. (62) Medical records 1 yr 
ullivan et al. (15) Medical records 3 yrs 
ulop et al. (58) SCID interview 6 months 
oenig et al. (48) DIS interview 1 yr 
umsfeld et al. (14) MOS-D 6 weeks 
e Denus et al. (49) Medical records 7.5 months 
aris et al. (50) Medical records 4 yrs 
reedland et al. (60) DIS interview 1 yr 
iang et al. (12) DIS interview 1 yr 
unger et al. (13) HADS-D 24 months 
urberg et al. (63) Zung 2 yrs 
ullivan et al. (11) PRIME-MD interview 3 yrs 
accarino et al. (38) Geriatric depression 6 months 
ES-D  Center for Epidemiological Studies–Depression; DIS  Diagnostic Inter
OS-D  Medical Outcomes Study–Depression; NA  not available; PRIME-MD  P
or DSM-IV.own by depression assessment method, rates of depression
emained similar for inpatient and outpatient samples.
Analyses based on geographic location showed nearly
dentical point estimates of prevalence of depression rates in
F patients in the U.S. and Canada (20.3%) and Europe
21%).
linical outcomes. Table 3 provides a description of the 14
rospective investigations reporting associations between de-
ression and HF-related events (11–15,38,44,48–50,58,60–
3). The studies included a range of depression assessment
ools, protocol lengths, and sample sizes. Women composed
significant percentage of most study samples. Outcome
ategories included: 1) the relationship between depression
nd HF incidence in a healthy or at-risk sample; 2)
epression effects among HF patient samples on measures
f health care cost or health care system use; and 3) the
mpact of depression on mortality and/or secondary events
ot including hospitalization.
F incidence. Two studies reported data concerning de-
ression and HF development. Covariate adjusted hazard
atios (including age and disease severity) were 1.5 and 2.6
n these studies, which followed up participants for 4.5 and
4 years, respectively. The stronger relationship between
epression and HF incidence was noted in the protocol
nrolling “high risk” patients with systolic hypertension (61).
t/Outpatient Status and Diagnostic Threshold
Depression Prevalence Rates Among Patient Classifications
Using Liberal Cutoffs*
Patient
Classification
Prevalence
Rate (SD)
Number of Studies,
(Patients)
Inpatient 0.38 (0.13) 7 (2,667)
Outpatient 0.38 (0.11) 11 (1,036)
Combined 0.32 (0.06) 5 (1,673)
is by an MD or PhD mental health professional, or use of a stringent questionnaire
en Depression and Clinical Outcomes
Sample Size % Women Outcome(s)
4,538 57 Incident HF
2,501 58 Incident HF
139,089 NA Health service use, hospitalization
1,098 53 Health care costs, clinical events
203 53 Hospitalization
107 52 Hospitalization
466 24 Hospitalization
171 36 Clinical events
396 26 Hospitalization, clinical events
60 57 Hospitalization, mortality
357 36 Hospitalization, clinical events
209 28 Clinical events
119 29 Clinical events
142 23 Clinical events
391 49 Clinical events
chedule; HADS-D  Hospital Anxiety and Depression Scale; HF  heart failure;atienetwe
view S
rimary Care Evaluation of Mental Disorders; SCID  Structured Clinical Interview
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Depression and Heart Failure October 17, 2006:1527–37ealth care use and hospitalization. A total of 7 studies
eported information concerning relative rates of health care
se among HF patients with lower versus higher levels of
epression, including 6 studies comparing rates of rehospi-
alization. Despite the wide range of use variables, the data
ndicate a consistent pattern of increased health care usage
or patients with depression. These end points included a
ore than 2-fold risk of emergency room visits for de-
ressed versus nondepressed patients (62); a 29% increase in
otal health care costs (aggregated from separate measures of
ental health visits, and inpatient and outpatient treat-
ents) for patients with a depression diagnosis or receiving
reatment for depression versus those without depression
11); and increases in both short-term (4-week) and longer-
erm (6-month) medical encounters (58).
Among studies reporting hospitalization comparisons, pro-
ocol lengths varied from 6 weeks to more than 4 years.
rotocol length influenced the relationship between depression
everity and rehospitalization rates. Briefer studies typically
uggested no or small differences during the initial months
fter discharge (60), compared with more substantial differ-
nces appearing by 1 year of follow-up. The study by Koenig
48) provides an illustration of this theme. Among 39 HF patients
ith high scores on the Center for Epidemiologic Studies–
epression scale, inpatient readmission rates were 31.6%, 54.8%,
0.7%, and 25% at 3, 6, 9, and 12 months, respectively. Rates over
he same intervals among 45 nondepressed patients in this sample
ere 35.7%, 27.8%, 17.7%, and 16.1%.
ortality and associated clinical events. Eight indepen-
ent cohort studies, ranging in length from 6 months to
ore than 4 years, tracked the incidence of mortality and
ssociated cardiac events (e.g., heart transplantation, new
ardiac events) in association with depression. Figure 2
llustrates the range of effects from these studies.igure 2. Effect sizes and 95% confidence intervals among studies reportin
8 studies).Study protocols included a variety of definitions of
epression, including elevated questionnaire scores, diag-
oses based on information in the patients’ medical records,
nd the administration of a diagnostic interview. The
umber of studies including an interview-based diagnosis
as insufficient to make comparisons between depression
ymptoms and mood disorders in the prediction of clinical
utcomes.
The aggregated risk estimate from the 8 studies suggested
greater than 2-fold risk of death and associated clinical
vents for HF patients with heightened depressive symp-
oms or a depressive disorder (relative risk  2.1, 95%
onfidence interval 1.7 to 2.6). Despite the variation across
tudies noted above, this estimation is based on homoge-
ous results (heterogeneity p  0.87; I2  0%). Overall, the
ombined evidence did not indicate that the relationship
etween depression and HF outcomes differed by length of
ollow-up, however, the results of individual studies suggest
hat this is an area requiring additional study. Junger et al.
13) reported depression and mortality associations by
-month intervals across 30 months of follow-up, indicating
strong, graded relationship over time. In contrast, differ-
nces in death rates between depressed and nondepressed
F patients were stable across 1-, 2-, and 3-year estimates
n a separate protocol (50). Few if any of the studies to date
ncluded samples sizes that were adequately powered to
etect differences in short-term mortality and clinical event
ates.
reatment effects. Table 4 summarizes the methodologic
haracteristics and intervention outcomes for the 6 articles
ncluded as treatment studies (56,64–68). Each study com-
rised a pre-post design using HF patients among whom
epression severity was assessed using a validated question-
aire to gauge treatment effectiveness. Two studies alsog associations between depression and mortality and secondary events
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October 17, 2006:1527–37 Depression and Heart Failureeported patients’ results on the 6-min walk test before and
fter treatment to determine whether objective measures of
bility were affected by the intervention. In addition, some
f the studies also reported results of other variables on
hich HF patients experienced changes attributed to the
ntervention, such as physical abilities (e.g., VO2max, weight
ifted), physiological measurements (e.g., weight, blood
ressure, QT intervals), and scores on other questionnaires
e.g., quality of life, anxiety).
The treatment studies generally suffered from 1 or more
ethodologic flaws, including small samples, brief treat-
ent durations, and a lack of a placebo or control group
omparison. The mean decrease in depression scores, ex-
ressed in Cohen d units, was 0.42, translating to just over
0% of a standard deviation difference between groups.
owever, this result was skewed by large depression symp-
om reductions observed in 1 study (56). The median
ohen d value across all studies was 0.16 (i.e., 16% of a
tandard deviation difference between treated and untreated
roups, a modest difference by most standards). Assessing
epression symptom reductions separately for studies that
sed a nonpharmacologic intervention yielded a mean
ohen d value of 0.29 in depression reduction.
ISCUSSION
his meta-analysis provides evidence supporting a moderate
o high prevalence of depression among patients with HF,
n increased risk of mortality and clinical events among HF
atients with depressive symptoms, and reductions in de-
ressive symptoms resulting from a variety of treatment
nterventions. The relationship between depression and HF
s a relatively new but rapidly expanding area of interest in
ardiology research. In fact, very few articles were published
n this topic before 1990, but the key word searches used
dentified more than 100 articles published on the topics of
epression and other psychosocial factors in HF patients
ince that time. This increase in research attention coincides
ith the growth in HF as a health care problem in the U.S.
uring the past 10 years, HF was the fastest growing form
f cardiovascular disease, and accounted for more than 1
illion annual hospital admissions and an estimated $60
illion in annual health care expenses (69). Because patients
ith HF face high rates of debilitation and mortality, the
tudy of depression characteristics in this population is a
ritical research area in the pursuit of improved quantity and
uality of their lives. Abundant evidence suggests that
epression is under-recognized and undertreated in cardiac
opulations (3,10,70); this review begins to address some of
he consequences of this treatment milieu.
epression prevalence in HF. The overall aggregated
oint estimate prevalence rate calculated in this study
21.6%) indicates that HF patients experience clinically
ignificant depression at a rate similar to the 15% to 20%
evels cited for CAD patients (71,72), and at 2 to 3 timesthe rate of the general population (73). Considering theTa
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Depression and Heart Failure October 17, 2006:1527–37ypically worse prognosis for individuals with HF as op-
osed to CAD or myocardial infarction, this rate of depres-
ion may seem modest. However, this combined depression
stimate is much lower than that suggested in a number of
F studies (48), a discrepancy that seems from this review
o be a result of defining depression on the basis of elevated
ymptom severity from questionnaires rather than a diag-
ostic interview. Individual study prevalence estimates
anged from 9% to 60%, suggesting a considerable degree of
eterogeneity.
Explaining the heterogeneity of reported depression rates
as a secondary goal of this review. The moderators
xplored in association with depression prevalence included
epression assessment method, conservative versus liberal
utoff used to classify depression’s presence, inpatient versus
utpatient samples, HF severity, ethnicity, age, and gender.
rom these analyses, depression assessment methods (i.e.,
uestionnaire versus diagnostic interview) and the liberality
f their cutoffs as well as HF severity seem to have the
argest impact on reported depression rates. With one
xception (17), differences in depression and HF severity
ased on patient age were not reported in a form that could
rovide an effective assessment of this relationship. Mean
ges between study samples were likewise too similar to
dentify age-related trends. Depression rates may also differ
ccording to HF characteristics that affect symptom severity
r degree of disability (e.g., systolic vs. diastolic HF, or HF
ith preserved vs. depressed ejection fraction). At present,
e have almost no information concerning depression
ifferences across subclasses of HF patients. Although
nteractions among the above moderator factors are poten-
ially very interesting for understanding depression preva-
ence in HF and could be approached using multilevel
odeling methods (74), we were not able to address these
uestions systematically because of inconsistent reporting of
he moderator factors across studies.
Awareness of which demographic characteristics and/or
ethods of assessment are likely to result in a higher or
ower detection rate of depression may help researchers and
linicians alike. For example, researchers examining this
elationship could design their studies with greater precision
o answer their specific research questions. Likewise, clini-
ians (e.g., primary care physicians, cardiologists, psychia-
rists, and psychologists) would be equipped with the
nowledge of the idiosyncrasies associated with the identi-
cation of major depression versus depressive symptoms
mong their patients; hence, clinicians could assess their
atients with different criteria depending on the severity of
epression they intend to identify and attempt to treat.
umerous studies from the depression and CAD literature
ndicate that depression severity is linearly associated with
linical outcomes (3–5), suggesting that the presence of a
ajor depressive episode is not necessary as a standard for
ntervening. No single method or cutoff is necessarily the
est; rather, each is different and should be used with
ppreciation of its implications and limitations. tepression and clinical outcomes. Across a range of
ortality, health care use, and associated clinical event
utcomes investigated in the prospective studies of depres-
ion and HF, aggregate results indicated a substantially
orse prognosis for HF patients with more severe depres-
ive symptoms. Nearly all of the clinic outcome studies of
epression adjusted for multiple covariates (e.g., age,
YHA functional class, ejection fraction), suggesting that
epression effects are reasonably robust to demographic and
isease severity characteristics. Although these findings are
onsistent with depression effects on mortality in cardiac
isease patients described in recent reviews (7,8), the mor-
ality results were further reinforced by equally large differ-
nces in hospital readmission and health care use by
epressed versus nondepressed HF patients. This pattern
uggests that any interventional efforts targeting depression
n HF should consider a broad category of clinical outcomes
o accurately assess potential benefits. Importantly, the
ncreased event risk associated with depression within the
F population has only been examined in studies with
elatively small sample sizes, many of which were marginally
owered to detect clinically significant effects, particularly
ver shorter time intervals. We can likewise only speculate
t this stage regarding differences in the depression and HF
utcomes relationship based on factors such as NYHA class,
reatment adherence, or age. Thus, although this meta-
nalysis was able to quantify a more precise magnitude of
he increased risk of clinical events among depressed pa-
ients, a clear need for additional research remains.
Unfortunately, outcome variables of interest such as HF
ncidence and health care costs did not lend themselves to
eta-analytic procedures because of an insufficient number
f studies. The data from existing studies are suggestive of
higher risk of HF development among those with more
evere depressive symptoms, as well as higher costs resulting
rom an increased use of health care services. We hope that
rawing attention to the current paucity of data regarding
hese topics will provide direction to researchers working in
his area. Finally, in the context of prospective studies,
lmost no information concerning changes in depression
ver time is available. Because individuals’ depression symp-
oms are likely to change over time, depression should
deally be assessed at multiple intervals throughout studies’
urations to understand possible biobehavioral pathways
inking depression with HF events (75,76). Heart failure
nd depression share several biological mechanisms. Heart
ailure (75–77) and depression (78–81) are associated with
ympathetic activation and elevated proinflammatory cyto-
ines, including interleukin (IL)-6, tumor necrosis factor
lpha, and IL-1. The additive effects of the inflammation
ound in depression likely adversely affect the heart (82–84).
xercise programs reduce IL-6 and tumor necrosis factor
lpha levels in HF (85,86). Pharmacologic and exercise
reatments for depression reduce depressive symptoms and
ight reduce accompanying inflammation (87–89), poten-ially producing more favorable HF-related clinical out-
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1535JACC Vol. 48, No. 8, 2006 Rutledge et al.
October 17, 2006:1527–37 Depression and Heart Failureomes in the patients. At the very least, reducing symptoms
f depression could be expected to improve adherence to
F treatment regimens (90,91).
epression treatment studies among HF patients. Fi-
ally, the treatment/intervention section proved to be the
ost difficult to quantify because of the following factors:
mall number of identified studies documenting changes in
retreatment versus posttreatment depression severity, brief
urations, small sample sizes (many were pilot studies), and
ubstantial heterogeneity in the types of interventions. We
ere not able to quantify the quality or appropriateness of
he interventions for the target patient groups. Some of the
harmacologic interventions used, such as digoxin, do not
ave specific antidepressant effects, and may underestimate
otential treatment benefits achievable via interventions
ocused more specifically on depression symptoms. Unlike
he larger depression and CAD literature (10,92), no study
o date has investigated the effects of a depression interven-
ion on objective clinical outcomes such as survival or
econdary cardiac events in an HF population. Despite these
imitations, a general pattern of decreased depressive symp-
oms and increased physical abilities (as measured by the
tandard 6-min walk test) was observed across the treatment
tudies. Although these preliminary results are promising,
he most important aspect of this section is the need for
ore studies with larger sample sizes, replicable interven-
ions (especially interventions with a behavioral or psycho-
ocial component), and longer durations.
tudy limitations. A large number of articles describe
sychosocial characteristics other than depression among
F patients. Anxiety, social support and social isolation,
nd quality of life are each examples of other topics of
sychosocial research in the HF literature (93–95) that
erit review but that are beyond the scope of this review.
We did not include unpublished articles or articles from
on–peer-reviewed journals, which are more likely to con-
ain negative associations (96). Additional articles that
ontain findings relevant to the areas covered in this article
ay have been missed because of a mismatch between our
ey word and abstract searches and the key words in their
itles or abstracts. Lastly, the protocol descriptions in a
umber of studies suggested that additional information
hat could have been useful in the meta-analytic tests was
ollected, but we were limited to the data as reported
ecause of incomplete reporting or inability to contact the
tudy investigators.
ummary. We conducted a focused quantitative review of
he depression and HF literature concerning questions
bout depression prevalence, clinical outcomes, and treat-
ent impact. This article is among the first to apply
eta-analytic methods to the growing field of depression
nd HF. Across published studies concerning depression
revalence, associations with clinical outcomes, and
hanges resulting from treatment interventions, several
eneral conclusions can be drawn: 1) depression is com-
on among patients with HF, with approximately 1 in 5
1atients meeting criteria for major depression based on
nterview methods, and substantially higher rates of clini-
ally significant depression are present among patients
ssessed with questionnaires (vs. diagnostic interviews) or
ith more severe HF; 2) rates of mortality, clinical events,
ehospitalization, and general health care use are markedly
igher among HF patients reporting more severe depres-
ion; and 3) studies describing depression treatments among
F patients are too small and heterogeneous to permit
efinitive conclusions regarding intervention effectiveness.
hese results identify areas requiring further development,
aise novel questions, and provide information on depres-
ion prevalence that can help researchers design studies with
ppropriate depression measures and adequately powered
ample sizes.
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